Mayo Clinic has developed a new and more powerful test for detection and monitoring of plasma cell disorders: Plasma Cell DNA Content and Proliferation, Bone Marrow. Continue reading to learn more and to view a video discussing this new test.
The enterovirus PCR test is the recommended testing method for the detection of acute disease because it offers the advantages of rapid turnaround times, detection of circulating virus’ RNA, and improved positive predictive value (PPV).
Our comprehensive testing for celiac disease and inflammatory bowel disease evaluates patients suspected of having celiac disease, including patients with compatible symptoms, patients with atypical symptoms, and individuals at increased risk. We also offer a variety of interactive, step-by-step algorithms that provide the most appropriate selection of tests for each patient, while maintaining the highest possible sensitivity and specificity.
Over 1 million hips are implanted each year worldwide. Adverse reaction to metal debris (ARMD) occurs in a small number of patients with metal-on-metal hip replacements. Evaluation of serum chromium and cobalt concentration can help determine the degree of metal-on-metal orthopedic implant deterioration.
Mayo Clinic offers a test to assess for biliary tract malignancy through the combination of cytology and molecular testing by fluorescence in situ hybridization (FISH).
R. Jeffrey Karnes, M.D., addresses the controversy over PSA test use and its effectiveness in prostate cancer screening and discusses what constitutes the best screening methods and programs.
The CellSearch Circulating Tumor Cell (CTC) test is a simple blood test that helps oncologists in assessing the prognosis of patients with metastatic breast, colorectal, or prostate cancer.
Autoantibody tests performed on serum and spinal fluid aid in the diagnosis of autoimmune disorders of the brain, nerve, and muscle that are often a reflection of immune responses initiated by unsuspected cancer.